Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 16, Issue 7, Pages 717-729Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2016.1184979
Keywords
Advanced gastric cancer; chemotherapy; target therapy; metronomic chemotherapy; immunotherapy
Categories
Ask authors/readers for more resources
Introduction and areas covered: We analysed the results of the main clinical studies looking at patients with advanced gastric or esophagogastric junction cancer, in order to differentiate between what is already clinical evidence and what is a promise for the cure of such patients. Thus, achievements from key studies, which had been purposely directed at chemotherapy, molecular target therapies and immunotherapy in both first and second-line setting were analysed. Metronomic chemotherapy, which consists of the administration of continuative low-dose anticancer drugs, was considered also. Expert commentary: It was found that patients included in experimental arms of randomized trials compared with controls have often benefited from a statistically significant extension of overall survival. However, further studies are awaited to bring new drugs into clinical practice and to validate candidate biomarkers predictive of response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available